Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Associated Press
The National Institutes of Health on Wednesday announced a joint initiative with pharmaceutical companies to spur the development of drugs to address the opioid epidemic. It will start with a series of private workshops over the next six weeks and focus on three areas:
- Developing interventions for reversing overdoses, including stronger, longer-lasting medicines to counteract synthetic opioids and, in the long-term, potentially wearable devices that sense an overdose and automatically inject naloxone.
- New treatments for opioid addiction. The NIH is investigating new medications, beyond the three currently available, repurposing and reformulating approved drugs (like lorcaserin), and even vaccines that would spur the production of antibodies against opioids and prevent them from entering the brain.
- Non-addictive treatments for chronic pain. The NIH plans to target two separate pain-signaling pathways in hopes of developing an alternative to synthetic opioid medications. They are also researching compounds that target other opioid receptors and ways to formulate drugs so they can't be snorted or injected.